KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.90

Rapid and Sustained Response of Biochemically Uncontrolled Acromegaly to Once-daily Oral Paltusotine Treatment.

Beverly M K Biller, Alessandra Casagrande, Atanaska Elenkova, Cesar L Boguszewski, Raquel S Jallad, Beibei Hu, Erika Hubina, Pouneh K Fazeli, Maria Fleseriu, Peter J Snyder, Christian J Strasburger, Martin Bidlingmaier, Yining Zhao, Beatriz Soares, Peter J Trainer, R Scott Struthers, Alan Krasner, Mônica R Gadelha

J Clin Endocrinol Metab 111(4) e1050-e1063

PMID41128642
PMCIDPMC13016795
DOI10.1210/clinem/dgaf579
发表日期2025-10-23
入排依据:The study is a Phase III randomized trial of a drug for acromegaly, which is an endocrine disorder, not a human malignant neoplasm. Therefore, it is excluded on oncology grounds. Additionally, the primary endpoint is IGF-I normalization (binary) and changes in IGF-I levels (continuous), not a time-to-event efficacy endpoint like OS, PFS, DFS, EFS, RFS, TTP, or survival analysis with Kaplan-Meier/HR.
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 7 张 PMC Figure,均未识别为 KM 图:Figure 1.:研究设计图;Figure 2.:图注未提示 KM 曲线;Figure 3.:图注未提示 KM 曲线;Figure 4.:图注未提示 KM 曲线;Figure 5.:图注未提示 KM 曲线;另有 2 张未列出。
摘要

摘要

CONTEXT: Paltusotine is a nonpeptide, selective somatostatin receptor 2 agonist in development as once-daily oral treatment for acromegaly. OBJECTIVE: To evaluate efficacy and safety of paltusotine in patients with biochemically uncontrolled acromegaly not currently receiving medical therapy. METHODS: In this phase 3, randomized, double-blind, placebo-controlled trial, adults with medically untreated acromegaly at randomization (stratum 1: medication-naïve or off acromegaly medications ≥4 months [IGF-I ≥ 1.3 × upper limit of normal {ULN}]; stratum 2: controlled on a somatostatin receptor ligand and underwent washout [IGF-I increase ≥30% to ≥1.1 × ULN]) received paltusotine or placebo for 24 weeks. RESULTS: A total of 111 patients (stratum 1, n = 82; stratum 2, n = 29) enrolled (paltusotine, n = 54; placebo, n = 57). The primary endpoint of IGF-I normalization at 24 weeks was met in 55.6% of paltusotine-treated patients vs 5.3% for placebo (odds ratio [OR]: 42.81; 95% CI, 8.44-455.82; P < .0001), with superiority to placebo in both strata. Paltusotine treatment decreased IGF-I in 92.6% of patients within the first 4 weeks. All secondary endpoints were met: mean (±SE) change in IGF-I of -0.82 ± 0.08×ULN with paltusotine vs 0.09 ± 0.08×ULN with placebo (P < .0001); IGF-I < 1.3×ULN in 66.7% vs 14.0% of patients (OR: 18.32; 95% CI, 5.64-79.16; P < .0001); GH (5-sample mean) < 1.0 ng/mL in 57.4% vs 17.5% (OR: 7.59; 95% CI, 2.78-23.48; P < .0001); mean (±SE) change in Acromegaly Symptom Diary score of -2.7 ± 1.4 vs 2.8 ± 1.4 (P = .004). Most adverse events were acromegaly symptoms or mild, transitory gastrointestinal effects characteristic of somatostatin receptor ligands (eg, diarrhea, abdominal pain). Pituitary tumor volume was stable or reduced in paltusotine-treated patients. CONCLUSION: IGF-I normalized in significantly more patients with uncontrolled acromegaly treated with paltusotine vs placebo. Paltusotine was associated with rapid, sustained IGF-I reduction, significant symptom improvement and stable or reduced pituitary tumor size and was well tolerated.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(7,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1.Study design. *Medication-naïve, n = 46; previously treated (off acromegaly medications for ≥4 months), n = 36. † Patients received rescue medication (injected depot somatostatin receptor ligand) if the following criteria were met: 2 consecutive IGF-I levels ≥1.5 × ULN at the highest dose of study medication (60 mg/day) and exacerbation of acromegaly symptoms for ≥2 weeks, as assessed by the investigator.
非 KM Figure
Figure 2.Patient disposition. *Inadequately controlled diabetes, clinically significant concomitant disease, active malignant disease within the past 5 years, history of hepatitis B or HIV, QT interval prolonged, elevated liver enzymes, high-risk pituitary tumor, symptomatic cholelithiasis, pregnant/lactating female, use of exclusionary medications.
非 KM Figure
Figure 3.(A) Primary endpoint: proportion of patients with IGF-I ≤ 1.0 × ULN at the end of the randomized controlled phase. The primary endpoint was based on the average of IGF-I values at weeks 22 and 24. If only 1 measurement was available (week 22 or 24), it was used to evaluate the primary endpoint. Patients who discontinued the assigned treatment before week 24 for any reason (including rescue) or had missing IGF-I values at both weeks 22 and 24 were considered not to have met the primary endpoint. Odds ratio is from exact logistic regression models, with treatment group as a factor and stratum as a covariate (for the overall analysis only). (B) Mean change from IGF-I baseline at each assessment. For patients who discontinued randomized treatment before week 24, the last value before rescue (or study discontinuation) was carried forward.
非 KM Figure
Figure 4.Change in IGF-I at the end of randomized treatment, by acromegaly treatment history. (A) All patients, stratum 1 (not medically treated), and stratum 2 (washed out). (B) Medication-naïve and previously treated patients (from stratum 1). *Comparison of paltusotine vs placebo using analysis of covariance.
非 KM Figure
Figure 5.Change in individual IGF-I concentrations from baseline to the end of randomized treatment (average of weeks 22 and 24 or last measurement prior to rescue).
非 KM Figure
Figure 6.Least-squares mean change from baseline at the end of randomized treatment in Acromegaly Symptom Diary total score (ASD; secondary endpoint) (A) for the overall study population and (B) by stratum. Higher scores indicate worse symptom severity. Treatment difference from worst-rank score analysis of covariance with treatment group as a factor and stratum as a covariate.
非 KM Figure
Figure 7.Least-squares mean change from baseline at the end of randomized treatment for Acromegaly Symptom Diary (ASD) item scores in the overall study population. Higher scores indicate worse symptom severity. * P < .05 vs placebo; ** P < .01 vs placebo from analysis of covariance with treatment group and stratum as fixed effects and baseline value as a covariate.
非 KM Figure